USA - NASDAQ:IMPL - US45258K1097 - Common Stock
Taking everything into account, IMPL scores 1 out of 10 in our fundamental rating. IMPL was compared to 534 industry peers in the Biotechnology industry. IMPL may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, IMPL is valued expensive at the moment.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -204.4% | ||
| ROE | N/A | ||
| ROIC | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 57.3% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -18.82 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.27 | ||
| Quick Ratio | 0.21 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
0.2411
-0.17 (-41.79%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.3 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -204.4% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 57.3% | ||
| FCFM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 252.44% | ||
| Cap/Sales | 10.87% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.27 | ||
| Quick Ratio | 0.21 | ||
| Altman-Z | -18.82 |
ChartMill assigns a fundamental rating of 1 / 10 to IMPL.
ChartMill assigns a valuation rating of 1 / 10 to IMPEL PHARMACEUTICALS INC (IMPL). This can be considered as Overvalued.
IMPEL PHARMACEUTICALS INC (IMPL) has a profitability rating of 1 / 10.
The financial health rating of IMPEL PHARMACEUTICALS INC (IMPL) is 0 / 10.
The Earnings per Share (EPS) of IMPEL PHARMACEUTICALS INC (IMPL) is expected to grow by 64.5% in the next year.